Ken Fisher’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.1M | Buy |
122,226
+9,984
| +9% | +$1.32M | 0.01% | 347 |
|
|
2025
Q4 | $15.9M | Buy |
112,242
+17,447
| +18% | +$2.53M | 0.01% | 352 |
|
|
2025
Q3 | $13.3M | Buy |
94,795
+7,255
| +8% | +$983K | ﹤0.01% | 375 |
|
|
2025
Q2 | $11M | Sell |
87,540
-7,717
| -8% | -$885K | ﹤0.01% | 400 |
|
|
2025
Q1 | $10.5M | Buy |
95,257
+3,153
| +3% | +$399K | ﹤0.01% | 409 |
|
|
2024
Q4 | $12.6M | Buy |
92,104
+23,834
| +35% | +$2.95M | 0.01% | 407 |
|
|
2024
Q3 | $7.87M | Buy |
68,270
+4,930
| +8% | +$676K | ﹤0.01% | 445 |
|
|
2024
Q2 | $8.72M | Sell |
63,340
-1,826
| -3% | -$250K | ﹤0.01% | 431 |
|
|
2024
Q1 | $8.99M | Buy |
65,166
+4,939
| +8% | +$675K | ﹤0.01% | 437 |
|
|
2023
Q4 | $7.94M | Sell |
60,227
-1,600
| -3% | -$184K | ﹤0.01% | 441 |
|
|
2023
Q3 | $6.96M | Sell |
61,827
-179
| -0.3% | -$18.8K | ﹤0.01% | 480 |
|
|
2023
Q2 | $5.85M | Sell |
62,006
-2,136
| -3% | -$209K | ﹤0.01% | 523 |
|
|
2023
Q1 | $6.49M | Sell |
64,142
-126
| -0.2% | -$13.1K | ﹤0.01% | 508 |
|
|
2022
Q4 | $7.68M | Sell |
64,268
-848
| -1% | -$99.3K | 0.01% | 485 |
|
|
2022
Q3 | $6.92M | Sell |
65,116
-5,362
| -8% | -$544K | 0.01% | 436 |
|
|
2022
Q2 | $6.87M | Sell |
70,478
-4,178
| -6% | -$386K | ﹤0.01% | 388 |
|
|
2022
Q1 | $7M | Buy |
74,656
+9
| +0% | +$763 | ﹤0.01% | 409 |
|
|
2021
Q4 | $6.36M | Buy |
74,647
+5,453
| +8% | +$502K | ﹤0.01% | 432 |
|
|
2021
Q3 | $6.64M | Buy |
69,194
+7,545
| +12% | +$713K | ﹤0.01% | 396 |
|
|
2021
Q2 | $6M | Buy |
61,649
+3,473
| +6% | +$333K | ﹤0.01% | 409 |
|
|
2021
Q1 | $5.66M | Buy |
58,176
+746
| +1% | +$78.2K | ﹤0.01% | 416 |
|
|
2020
Q4 | $5.5M | Sell |
57,430
-1,791
| -3% | -$173K | ﹤0.01% | 409 |
|
|
2020
Q3 | $5.7M | Sell |
59,221
-4,006
| -6% | -$463K | 0.01% | 384 |
|
|
2020
Q2 | $7.71M | Sell |
63,227
-1,340
| -2% | -$148K | 0.01% | 351 |
|
|
2020
Q1 | $5.59M | Sell |
64,567
-2,208
| -3% | -$216K | 0.01% | 345 |
|
|
2019
Q4 | $7.18M | Sell |
66,775
-6,252
| -9% | -$655K | 0.01% | 368 |
|
|
2019
Q3 | $6.58M | Sell |
73,027
-1,393
| -2% | -$130K | 0.01% | 408 |
|
|
2019
Q2 | $6.28M | Buy |
74,420
+47,257
| +174% | +$3.88M | 0.01% | 408 |
|
|
2019
Q1 | $2.39M | Sell |
27,163
-477
| -2% | -$39.9K | ﹤0.01% | 500 |
|
|
2018
Q4 | $1.97M | Sell |
27,640
-507
| -2% | -$48.6K | ﹤0.01% | 522 |
|
|
2018
Q3 | $3.46M | Sell |
28,147
-3,195
| -10% | -$363K | ﹤0.01% | 463 |
|
|
2018
Q2 | $3.08M | Buy |
+31,342
| New | +$2.81M | ﹤0.01% | 491 |
|
|
2018
Q1 | – | Sell |
-5,025
| Closed | -$390K | – | 807 |
|
|
2017
Q4 | $390K | Sell |
5,025
-28
| -0.6% | -$1.91K | ﹤0.01% | 684 |
|
|
2017
Q3 | $310K | Buy |
+5,053
| New | +$267K | ﹤0.01% | 678 |
|
Other funds holding NBIX
VPM
VCM
Ken Fisher's NBIX Position: Q1 2026 in Review
Ken Fisher increased its Neurocrine Biosciences (NBIX) stake by 8.9% in Q1 2026, buying an estimated $1.32M and bringing the position to 122,226 shares worth $16.1M. The position accounts for 0.01% of the portfolio, ranked #347.
Ken Fisher first reported a position in NBIX in Q3 2017 and has held it in 34 quarters since. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Ken Fisher held 122,226 shares of Neurocrine Biosciences worth $16.1M as of Q1 2026.
- Ken Fisher bought 9,984 Neurocrine Biosciences shares in Q1 2026, an estimated $1.32M.
- Neurocrine Biosciences made up 0.01% of Ken Fisher's portfolio in Q1 2026, its #347 holding.
- Ken Fisher first reported a position in Neurocrine Biosciences in Q3 2017 and has held it in 34 quarters since.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.